| Novartis Pharma Schweiz AG - Exelon Patch 10, transdermales Pflaster | | 58078 | | 02 | | Exelon Patch 10 | | transdermales Pflaster | | N06DA03 | | Rivastigmine | | 20.12.2007 | | |
| | Composition | | rivastigminum 18 mg, butylis methacrylatis et methylis methacrylatis polymerisatum, acrylic adhesive, int-rac-alpha-tocopherolum, silicone adhesive, dimeticonum, Trägermaterial: poly(ethylenis terephthalas), Drucktinte (Beige): ad praeparationem pro 10 cm², cum liberatione 9.5 mg/24h. | | Packungsbestandteile | | Transdermal patch | | | | | Active Agent | Dose |
|---|
| Rivastigmine | 18 mg |
| | BAG: Active Agent | Dose |
|---|
| Rivastigmine | 18 mg |
| | | | Inactive agents | Dose | additional_information |
|---|
| | | | | | | | | | 9.5mg / 24h | | | Dimeticone | | | | | 10 cm | | | | | | | | | | | | | Trägermaterial | | | | |
| |
| |
|
